ABPWW
Abpro Holdings Inc
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 183.0K | 183.0K | 122.0K | 2.0M | 480.0K |
| Cost of Revenue | 284.0K | — | — | 9.8M | 8.6M |
| Gross Profit | (101.0K) | 183.0K | 122.0K | (7.7M) | (8.1M) |
| Operating Expenses | |||||
| R&D Expense | 881.0K | 3.0M | 4.3M | 9.8M | 8.6M |
| SG&A Expense | 10.7M | 7.1M | 7.6M | 9.0M | 6.8M |
| General & Admin Expense | 9.8M | 7.1M | 7.6M | 9.0M | 6.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.0M | — | — | (9.8M) | (8.6M) |
| Total Operating Expenses | 14.6M | 10.1M | 11.9M | 9.0M | 6.8M |
| Cost and Expenses | 14.7M | 10.1M | 11.9M | 18.7M | 15.5M |
| Operating Income (EBIT) | (14.6M) | (9.9M) | (11.7M) | (16.7M) | (15.0M) |
| Non-Operating | |||||
| Interest Income | 36.0K | 9.0K | 63.0K | 48.0K | — |
| Interest Expense | 1.2M | 387.0K | 23.0K | 248.0K | 17.0K |
| Net Interest Income | (1.1M) | (378.0K) | 40.0K | (200.0K) | (17.0K) |
| Other Non-Op Income/Expense | 454.0K | 2.7M | 40.0K | (200.0K) | 242.0K |
| Non-Operating Income (excl Interest) | (1.9M) | (3.1M) | (63.0K) | (48.0K) | — |
| EBT (Pre-Tax Income) | (14.1M) | (7.2M) | (11.7M) | (16.9M) | (14.7M) |
| Income Tax Expense | (58.0K) | — | — | 330.0K | — |
| Bottom Line | |||||
| Net Income | (14.0M) | (7.2M) | (11.7M) | (17.2M) | (14.7M) |
| Earnings from Cont. Ops | (14.0M) | (7.2M) | (11.7M) | (17.2M) | (14.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.2M) | (17.4M) | (11.7M) | (17.2M) | (14.7M) |
| Per Share | |||||
| Basic EPS | ($22.29) | ($23.10) | ($37.50) | ($55.50) | ($47.70) |
| Diluted EPS | ($22.29) | ($23.10) | ($37.50) | ($55.50) | ($47.70) |
| Revenue Per Share | $0.07 | $0.58 | $0.39 | $6.54 | $1.55 |
| Shares | |||||
| Basic Shares Outstanding | 2.6M | 313267 | 311900 | 310400 | 309133 |
| Diluted Shares Outstanding | 2.6M | 313267 | 311900 | 310400 | 309133 |
| Profitability Metrics | |||||
| EBITDA | (12.2M) | (6.2M) | (10.9M) | (15.8M) | (14.5M) |
| D&A | 436.0K | 622.0K | 792.0K | 856.0K | 523.0K |
| EBIT | (12.6M) | (6.8M) | (11.7M) | (16.6M) | (15.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025